Author

M. Diossy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 5 Organism:human· 5 Approach:statistical model· 5 Assay:whole-exome sequencing· 4 Assay:whole-genome sequencing· 4 Research Focus:gene regulatory network inference· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1

Frequent Co-Authors

I. Csabai· 5 shared Z. Szallasi· 5 shared Z. Sztupinszki· 5 shared O. Rusz· 4 shared S. Spisak· 4 shared V. Tisza· 4 shared J. Borcsok· 3 shared M. Krzystanek· 3 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

I. Csabai

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

A. Prosz, H. Duan, V. Tisza, P. Sahgal, S. Topka, G. T.Klus, J. Borscok, Z. Sztupinszki, T. Hanlon, M. Diossy, L. Vizkeleti, D. R. Stormoen, I. Csabai, H. Pappot, J. Vijai, , Z. Szallasi

This paper identifies NER deficiency as a targetable vulnerability in ccRCC, showing that 10% of patients may respond to irofulven based on mutational signatures and PTGR1 expression.

bioRxiv · Feb 7, 2023Cancer Biology

Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomas

A. Prosz, P. Sahgal, C. X. Morris, Z. Sztupinszki, J. Borcsok, M. Diossy, V. Tisza, S. Spisak, O. Rusz, I. Csabai, B. M. Huffman, H. Singh, J.-B. Lazaro, M. Cecchini, J. M. Cleary, , N. S. Sethi

This study identifies HR and NER deficiencies in gastric and esophageal adenocarcinomas and shows their responsiveness to platinum chemotherapy and PARP inhibitors.

bioRxiv · Jul 14, 2022 · PreprintCancer Biology

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic aberration based molecular signatures

M. Diossy, Z. Sztupinszki, J. Borcsok, M. Krzystanek, V. Tisza, S. Spisak, O. Rusz, J. Timar, I. Csabai, J. Moldvay, A. G. Pedersen, D. Szuts, Z. Szallasi

The paper identifies HRD-associated mutational signatures in lung cancer cases and links them to PARP inhibitor sensitivity and platinum response.

bioRxiv · Nov 28, 2019Cancer Biology

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancer

Z. Sztupinszki, M. Diossy, M. Krzystanek, J. Borcsok, M. Pomerantz, V. Tisza, S. Spisak, O. Rusz, I. Csabai, M. Freedman, Z. Szallasi

The paper identifies genomic aberration-based molecular signatures to detect homologous recombination deficiency in prostate cancer, finding that 5-8% of cases may benefit from PARP-inhibitor treatment.

bioRxiv · Jun 24, 2019 · PreprintCancer Biology

Breast cancer brain metastases show increased levels of genomic aberration based homologous recombination deficiency scores relative to their corresponding primary tumors

M. Diossy, L. Reiniger, Z. Sztupinszki, M. Krzystanek, K. M. Timms, C. Neff, C. Solimeno, D. Pruss, A. C. Eklund, E. Toth, O. Kiss, O. Rusz, G. Cserni, T. Zombori, B. Szekely, , Z. Szallasi

The paper compares HRD scores in primary breast cancer tumors and their brain metastases, finding higher HRD in metastases, suggesting potential changes in PARP inhibitor therapy strategies.

bioRxiv · Jan 5, 2018Cancer Biology